IGF-1 LR3: Dosage, Protocol, and Research Guide
Long-acting insulin-like growth factor with enhanced potency and reduced binding to IGF binding proteins
Mechanism
Modified IGF-1 with arginine substitution and 13-amino acid extension. 3x more potent than IGF-1 with 20-hour half-life. Reduced affinity for binding proteins increases bioavailability.
Protocol at a glance
| Starting dose | 40mcg |
|---|---|
| Maintenance dose | 40-100mcg |
| Maximum dose | 100mcg |
| Frequency | Daily |
| Typical duration | 4-6 weeks |
| Route | Subcutaneous or intramuscular |
| Injection site | Abdomen or target muscles |
| Timing | Post-workout or before bed |
Side effects
- Hypoglycemia
- Joint pain
- Potential organ growth
- Water retention
Contraindications
- Diabetes
- Active cancer
- Cardiac conditions
Protocol notes
- Longer half-life than regular IGF-1
- More potent than IGF-1
- Use with extreme caution
- Monitor blood glucose levels
- May cause organ enlargement with prolonged use
Frequently asked questions
What is IGF-1 LR3 and how does it differ from regular IGF-1?
IGF-1 LR3 is a modified insulin-like growth factor with a 13-amino acid extension and arginine substitution that fundamentally changes its pharmacokinetics. Unlike regular IGF-1, which has a half-life measured in minutes, IGF-1 LR3 has a 20-hour half-life. Additionally, IGF-1 LR3 exhibits reduced binding to insulin-like growth factor binding proteins, resulting in 3 times greater potency than unmodified IGF-1. These modifications mean IGF-1 LR3 remains active in circulation much longer, enabling once-daily dosing protocols.
What is the recommended dosing protocol for IGF-1 LR3 research?
In research protocols, IGF-1 LR3 is typically administered at a starting dose of 40 mcg daily, with maintenance dosing ranging from 40-100 mcg daily, with a maximum of 100 mcg daily. Administration is via subcutaneous or intramuscular injection, often timed post-workout or before bed. The extended half-life means once-daily administration is sufficient to maintain elevated levels. Research cycles typically last 4-6 weeks to balance potential benefits with safety considerations.
How long does IGF-1 LR3 remain active in the body?
IGF-1 LR3 has a half-life of approximately 20 hours, making it significantly longer-acting than regular IGF-1, which is cleared from circulation in minutes. This extended half-life is due to the peptide's reduced affinity for insulin-like growth factor binding proteins, allowing it to remain available in the bloodstream longer. The 20-hour half-life means steady-state concentrations are achieved within 3-5 days of daily dosing, and elimination takes several days after the final injection.
What are the main side effects of IGF-1 LR3?
Common side effects reported in research protocols include hypoglycemia due to enhanced insulin sensitivity, joint pain, water retention, and potential organ growth with prolonged use. The extended half-life of IGF-1 LR3 means any side effects may be more pronounced and longer-lasting than with shorter-acting variants. Blood glucose monitoring is essential, particularly in the initial phase of use. Cardiac function should also be monitored given the risk of cardiac hypertrophy with extended duration protocols.
Who should not use IGF-1 LR3?
IGF-1 LR3 is contraindicated in individuals with diabetes, active cancer, or cardiac conditions. The enhanced insulin sensitivity and potential for organ growth make it unsuitable for those with metabolic disorders or existing organ pathology. Additionally, the risk of hypoglycemia is elevated in this peptide, making it dangerous for anyone with glucose regulation disorders. Any individual considering IGF-1 LR3 should obtain medical clearance and baseline cardiac and metabolic assessments.
What health markers should be monitored while using IGF-1 LR3?
Blood glucose monitoring is critical, especially during the first week of IGF-1 LR3 administration and regularly throughout the protocol. Given the potential for cardiac hypertrophy and organ enlargement with prolonged use, cardiac function assessments such as ECG are recommended before starting and potentially during extended protocols. Regular blood work to assess metabolic markers and organ function is advisable. The extended half-life means effects persist for several days after discontinuation, requiring ongoing monitoring during this period.
How long should an IGF-1 LR3 research cycle last?
Research protocols typically limit IGF-1 LR3 use to 4-6 weeks to minimize the risk of irreversible organ enlargement and other complications associated with sustained elevated IGF-1 levels. Prolonged use may cause organ growth that persists even after discontinuation. The extended half-life means even after stopping administration, the peptide remains active for several days. Use should be strictly limited to approved research protocols and under medical supervision.
What is the mechanism of action for IGF-1 LR3?
IGF-1 LR3 works through a modified molecular structure that includes an arginine substitution and 13-amino acid extension. These modifications reduce the peptide's affinity for insulin-like growth factor binding proteins (IGFBPs), which normally limit IGF-1 availability in circulation. By decreasing IGFBP binding, IGF-1 LR3 achieves significantly higher bioavailability and is approximately 3 times more potent than unmodified IGF-1, with a 20-hour half-life that enables sustained effects.
More Athletic Performance peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.